Sitagliptin: dipeptidyl肽酶IV抑制剂用于治疗2型糖尿病。

文章的细节

引用

复制到剪贴板

米勒,圣翁奇EL

Sitagliptin: dipeptidyl肽酶IV抑制剂用于治疗2型糖尿病。

安Pharmacother。2006 Jul-Aug; 40 (7 - 8): 1336 - 43。

PubMed ID

16868220 (在PubMed

]

文摘

摘要目的:回顾药理学、药物动力学、安全,sitagliptin和功效,dipeptidyl肽酶IV (DPP-IV)抑制剂在2型糖尿病的管理。数据来源:MEDLINE(1966 - 2006年2月)进行搜索英文文章使用条款dipeptidyl肽酶IV抑制剂,肠促胰岛素,mk - 0431, sitagliptin。摘要从2004年和2005年美国糖尿病协会年会是作为数据来源。研究选择和数据提取:文章属于sitagliptin的药理学,药物动力学,综述了安全性和有效性。数据综合:Sitagliptin是强有力的,竞争力,可逆DPP-IV酶的抑制剂。这是消除肾,终端半衰期为11.8 - -14.4小时。在二期临床试验,sitagliptin被发现优于安慰剂治疗2型糖尿病。一个小试验的结果比较sitagliptin和格列吡嗪表明治疗都是类似的。sitagliptin还演示了使用时的效果与二甲双胍联用治疗。很少有不良反应报道。 Weight gain and hypoglycemia have not been seen with sitagliptin therapy. CONCLUSIONS: Based on its unique mechanism of action, sitagliptin will provide practitioners with an additional tool in the treatment of diabetes. Review of the literature to date implies sitagliptin may be effective as monotherapy in type 2 diabetes. In addition, existing evidence supports the use of sitagliptin as adjunct therapy to sulfonylureas and metformin. Another advantage of sitagliptin use is that it appears to be free from the adverse effects of weight gain and hypoglycemia that are associated with currently available treatments.

beplay体育安全吗DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Sitagliptin	Dipeptidyl肽酶4	蛋白质	人类	是的	抑制剂	细节